Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth

Clinical Cancer Research

Volumn 17, Issue 5, 2011, Pages 1001-1011

  Huang, Hanhua ^a   Lai, Jing Yu ^a   Do, Janet ^a   Liu, Dingguo ^a   Li, Lingna ^a   Del Rosario, Joselyn ^a   Doppalapudi, Venkata R ^a   Pirie Shepherd, Steven ^a   Levin, Nancy ^a   Bradshaw, Curt ^a,b   Woodnutt, Gary ^a   Lappe, Rodney ^a   Bhat, Abhijit ^a  

^a PFIZER INC   (United States)

^b Traversa Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN 2 ANTIBODY; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CD11B ANTIGEN; CD31 ANTIGEN; COVX BODIES; CVX 060; CVX 060T; CVX 2000; CVX 32; CVX 32T; CVX 37; CVX 51; CVX 87; DOCETAXEL; FLUOROURACIL; HYBRID PROTEIN; IRINOTECAN; PEPTIDE ANTIBODY; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; IC 50; MALE; MICROVASCULATURE; MONOCYTE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; SUBCUTANEOUS TISSUE TUMOR; TUMOR; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMANS; IMMUNOCONJUGATES; MACROPHAGES; MALE; MICE; MONOCYTES; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952271693     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2317     Document Type: Article

References (41)

1. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992;3:89-96.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
3. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010;10:575-85.
4. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nature Rev Mol Cell Biol 2009;10:165-77.
5. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002;3:411-23.
6. Bach F, Uddin FJ, Burke D. Angiopoietins in malignancy. Eur J Surg Oncol 2007;33:7-15. (Pubitemid 46156618)
7. Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol 2004;204:1-10. (Pubitemid 39214476)
8. Chung YC, Hou YC, Chang CN, Hseu TH. Expression and prognostic significance of angiopoietin in colorectal carcinoma. J Surg Oncol 2006;94:631-8.
9. Oka N, Yamamoto Y, Takahashi M, Nishitani M, Kanayama HO, Kagawa S. Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer. BJU Int 2005;95:660-3. (Pubitemid 40311493)
10. Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002;62:7124-9. (Pubitemid 35424109)
11. Dhiwakar M, Malone JP, Kay PA, Robbins KT, Ran S. Use of angiopoietin-1 expression in squamous cell carcinoma of the head and neck to predict disease-free survival. J Clin Oncol 2010;28Suppl:abstr 5542.
12. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006;12: 235-9. (Pubitemid 43214752)
13. De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 2007;28:519-24.
14. Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010;70:5270-80.
15. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-26. (Pubitemid 41317592)
16. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109:5276-85. (Pubitemid 46890548)
17. Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009;175:2159-70.
18. Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507-16. (Pubitemid 39469986)
19. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27:3557-65.
20. Coronella J, Li L, Johnson K, Pirie-Shepherd S, Roxas G, Levin N. Selective activity against proliferating tumor endothelial cells by CVX-22, a thrombospondin-1 mimetic CovX-Body. Anticancer Res 2009;29:2243-52.
21. Doppalapudi VR, Tryder N, Li L, Aja T, Griffith D, Liao FF, et al. Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies. Bioorg Med Chem Lett 2007;17:501-6. (Pubitemid 46073729)
22. Tesan T, Gustavsson H, Welen K, Damber JE. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgenin-dependent prostate cancer models. BJU Int 2008;102:1034-9.
23. Pietrowski D, Wiehle P, Sator M, Just A, Keck C. Regulation of the angiopoietin-2 gene by hCG in ovarian cancer cell line OVCAR-3. Horm Metab Res 2010;42:328-33.
24. Detjen KM, Rieke S, Deters A, Schulz P, Rexin A, Vollmer S, et al. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res 2010;16:420-9.
25. Ochiumi T, Tanaka S, Oka S, Hiyama T, Ito M, Kitadai Y, et al. Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int J Oncol 2004;24:539-47.
26. Hata K, Nakayama K, Fujiwaki R, Katabuchi H, Okamura H, Miyazaki K. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 2004;93:215-22. (Pubitemid 38429573)
27. Chae SS, Kamoun WS, Farrar CT, et al. Angiopoietin-2 interferes with anti-VEGFR-2- induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 2010;16:3618-27.
28. Bullock AJ, Zhang L, O'Neill AM, et al. Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC). J Clin Oncol 2010;28:4630 (Suppl.).
29. Hughes DP, Marron MB, Brindle NP. The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABIN-2. Circ Res 2003;92:630-6. (Pubitemid 36417697)
30. Tadros A, Hughes DP, Dunmore BJ, Brindle NP. ABIN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-1. Blood 2003;102:4407-9. (Pubitemid 37494102)
31. Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in endothelium. Mol Cell Biol 2009;29:2011-22.
32. Kim HZ, Jung K, Kim HM, Cheng Y, Koh GY. Adesigned angiopoietin-2 variant, pentameric COMP-Ang2, strongly activates Tie2 receptor and stimulates angiogenesis. Biochim Biophys Acta 2009;1793:772-80.
33. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene 2000;19:4549-52.
34. Reiss Y, Droste J, Heil M, Tribulova S, Schmidt MH, Schaper W, et al. Angiopoietin-2 impairs revascularization after limb ischemia. Circ Res 2007;101:88-96. (Pubitemid 47094627)
35. Cao Y, Sonveaux P, Liu S, Zhao Y, Mi J, Clary BM, et al. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res 2007;67:3835-44. (Pubitemid 46762171)
36. Lee OH, Fueyo J, Xu J, Yung WK, Lemoine MG, Lang FF, et al. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia 2006;8:419-28. (Pubitemid 43830749)
37. Lewis CE, De Palma M, Naldini L. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 2007;67:8429-32. (Pubitemid 47437413)
38. Rosen LS, Mendelson DS, Cohen RB, et al. First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. J Clin Oncol 2010;28:2524 (Suppl.).
39. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, et al. Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res Treat 2006;98:261-6. (Pubitemid 44195595)
40. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003;63:3403-12. (Pubitemid 36735901)
41. Hou HA, Chou WC, Lin LI, Tang JL, Tseng MH, Huang CF, et al. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 2008;32:904-12.